Sarepta Therapeutics Inc (SRPT)

129.12 -1.71 (-1.31%)
Closed USD Disclaimer
129.15 +0.03 (+0.02%)

Sarepta Therapeutics Inc Company Profile

Sector
Healthcare
Employees
1162
Equity Type
ORD
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Contact Information
Address
Cambridge,02142 United States
Phone
617 274 4000
Fax
-
Top Executives
Name
Age
Since
Title
Douglas S. Ingram 58 2017 President, CEO & Director
M. Kathleen Behrens 69 2009 Independent Chairwoman
Beverly L. Davidson 0 2015 Member of Strategic & Scientific Advisory Board
Hans Wigzell 83 2010 Chairman of Corporate Strategy Board & Independent Non-Employee Director
Louis M. Kunkel 0 2015 Member of Strategic & Scientific Advisory Board
Kenneth H. Fischbeck 0 2017 Member of Strategic & Scientific Advisory Board
Matthew Wood 0 2017 Member of Strategic & Scientific Advisory Board
Steven Gray 0 2019 Member of Scientific Advisory Board
Angela J. Russell 0 2020 Member of Scientific Advisory Board
Carsten Bonnemann 0 2019 Member of Scientific Advisory Board
Kay Davies 0 2019 Member of Scientific Advisory Board
Annemieke Aartsma-Rus 0 2019 Member of Scientific Advisory Board
Joy A. Cavagnaro 0 2019 Member of Scientific Advisory Board
Stephen L. Mayo 60 2021 Independent Director
Michael Chambers 48 2022 Independent Director
Kathryn J. Boor 64 2022 Independent Director
Claude Nicaise 70 2015 Independent Non-Employee Director
Richard Jon Barry 64 2015 Independent Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.